TY - JOUR
T1 - Oral lichen planus and oral lichenoid lesions
T2 - diagnostic and therapeutic considerations
AU - Al-Hashimi, Ibtisam
AU - Schifter, Mark
AU - Lockhart, Peter B.
AU - Wray, David
AU - Brennan, Michael
AU - Migliorati, Cesar A.
AU - Axéll, Tony
AU - Bruce, Alison J.
AU - Carpenter, William
AU - Eisenberg, Ellen
AU - Epstein, Joel B.
AU - Holmstrup, Palle
AU - Jontell, Mats
AU - Lozada-Nur, Francina
AU - Nair, Raj
AU - Silverman, Bud
AU - Thongprasom, Kobkan
AU - Thornhill, Martin
AU - Warnakulasuriya, Saman
AU - van der Waal, Isaäc
PY - 2007/3
Y1 - 2007/3
N2 - Several therapeutic agents have been investigated for the treatment of oral lichen planus (OLP). Among these are corticosteroids, retinoids, cyclosporine, and phototherapy, in addition to other treatment modalities. A systematic review of clinical trials showed that particularly topical corticosteroids are often effective in the management of symptomatic OLP lichen planus. Systemic corticosteroids should be only considered for severe widespread OLP and for lichen planus involving other mucocutaneous sites. Because of the ongoing controversy in the literature about the possible premalignant character of OLP, periodic follow-up is recommended. There is a spectrum of oral lichen planus-like ("lichenoid") lesions that may confuse the differential diagnosis. These include lichenoid contact lesions, lichenoid drug reactions and lichenoid lesions of graft-versus-host disease. In regard to the approach to oral lichenoid contact lesions the value of patch testing remains controversial. Confirmation of the diagnosis of an oral lichenoid drug reaction may be difficult, since empiric withdrawal of the suspected drug and/or its substitution by an alternative agent may be complicated. Oral lichenoid lesions of graft-versus-host disease (OLL-GVHD) are recognized to have an association with malignancy. Local therapy for these lesions rests in topical agents, predominantly corticosteroids.
AB - Several therapeutic agents have been investigated for the treatment of oral lichen planus (OLP). Among these are corticosteroids, retinoids, cyclosporine, and phototherapy, in addition to other treatment modalities. A systematic review of clinical trials showed that particularly topical corticosteroids are often effective in the management of symptomatic OLP lichen planus. Systemic corticosteroids should be only considered for severe widespread OLP and for lichen planus involving other mucocutaneous sites. Because of the ongoing controversy in the literature about the possible premalignant character of OLP, periodic follow-up is recommended. There is a spectrum of oral lichen planus-like ("lichenoid") lesions that may confuse the differential diagnosis. These include lichenoid contact lesions, lichenoid drug reactions and lichenoid lesions of graft-versus-host disease. In regard to the approach to oral lichenoid contact lesions the value of patch testing remains controversial. Confirmation of the diagnosis of an oral lichenoid drug reaction may be difficult, since empiric withdrawal of the suspected drug and/or its substitution by an alternative agent may be complicated. Oral lichenoid lesions of graft-versus-host disease (OLL-GVHD) are recognized to have an association with malignancy. Local therapy for these lesions rests in topical agents, predominantly corticosteroids.
UR - http://www.scopus.com/inward/record.url?scp=33947217401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947217401&partnerID=8YFLogxK
U2 - 10.1016/j.tripleo.2006.11.001
DO - 10.1016/j.tripleo.2006.11.001
M3 - Article
C2 - 17261375
AN - SCOPUS:33947217401
SN - 1079-2104
VL - 103
SP - S25.e1-S25.e12
JO - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
JF - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
IS - SUPPL.
ER -